Leslie M. Randall, MD, MAS, ​professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massey Cancer Center, VCU Health, discusses the unmet need​s in platinum-resistant ovarian cancer.

 Limited treatment options are available for patients with platinum-resistant ovarian cancer, representing a clear unmet need, explains Randall.

 Although chemotherapy is the standard of care, the response rate is approximately 15% in this setting, says Randall.

As such, the FDA accelerated approval pathway, which offers a potential opportunity to fulfill these unmet needs, still stands in the United States, Randall concludes.

Videos

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

Leslie M. Randall, MD, MAS

Articles

Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer